Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

It’s one of the few cancers still considered incurable, and those diagnosed with multiple myeloma will likely die from the ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

For Townsville couple Darryl and Lauran Baillie, a detection machine would have meant Ms Baillie’s rare form of bone marrow ...

For Townsville couple Darryl and Lauren Bailey, a detection machine would have meant Ms Bailey’s rare form of bone marrow ...

GSK’s Blenrep is the only B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate for multiple myeloma, offering ...

India Bone Marrow Transplantation Market Size Expands at Steady CAGR 4.76% to Touch USD 1.3 Billion by 2030 Request To Download Free Sample of This Strategic Report @ ...

The StrataQuest software was coupled with TissueFAXS, offering a convenient workflow that could automatically acquire up to ...

1 Multiple myeloma originates in blood plasma cells — a type of cell found in bone marrow that is responsible for making antibodies. When these plasma cells become cancerous, they multiply ...